Tuesday, May 16 2023
08:50 AM – 09:15 AM PT
Clinical Protocol Implementation: Who sees the Patient and What is Needed?Clinical Infrastructure Treating the Patient/Acute Monitoring Phase I/II vs III vs IV
Kimberly Goodspeed, MD. University of Texas Southwestern Medical Center, TX
Disclosures: K. Goodspeed: 1; Commercial Interest i.e. Company X; Taysha Gene Therapy. 1; What was received? i.e. Honorarium; Research support. 1; For what role? i.e. Speaker; Speaker; clinical research & protocol development. 2; Commercial Interest i.e. Company X; Jaguar Gene Therapy. 2; What was received? i.e. Honorarium; Consulting fee. 2; For what role? i.e. Speaker; Speaker; Advisory Board participation. 3; Commercial Interest i.e. Company X; Astellas Gene Therapy. 3; What was received? i.e. Honorarium; consulting fee. 3; For what role? i.e. Speaker; Speaker, Advisory Board participation. 4; Commercial Interest i.e. Company X; Platform Q Health. 4; What was received? i.e. Honorarium; Honorarium. 4; For what role? i.e. Speaker; Speaker. 5; Commercial Interest i.e. Company X; Phacilitate. 5; What was received? i.e. Honorarium; Honorarium (travel funds). 5; For what role? i.e. Speaker; Speaker. 6; Commercial Interest i.e. Company X; COMBINEDBrain. 6; What was received? i.e. Honorarium; Uncompensated participation. 6; For what role? i.e. Speaker; Speaker; Co-chair advisory board.